Skip to content
BALCAO · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · SMALL CAP

Can B Corp. NASC

9 fiscal years on record · USD · FY2023 reported · SEC filings only
$2.2M
▼ 67.8% YoY
$-9.7M
$-1.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 2.2M
Revenue, FY2023 · full 9-year series below
Revenue $M Net income $M
FY2023 · Revenue 2.2 · Net income -9.7
2.5M5.0M-10.0M-20.0M
2015201820212023
Compound annual growth
+8.0%
+26.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +26.4% a year over the five years to FY2023.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−452 cents
lost on every revenue dollar
Operating margin Net margin
FY2023 · Operating -347.3% · Net -451.7%
-500%-1000%
201520192023
ROE
FY2022 · ROE -358.9%
-1000%-2000%-3000%
201520192023
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2023 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -1.3
-3M-6M
201520192023
Net buybacks $ Dividends $
FY2020 · Dividends · · Net buybacks 260000.0
100000200000
2020

Total assetsUSD 10.1M
EquityUSD -1.0M
CashUSD 34,006.00
Current ratio0.48×

Equity funds -10% of total assets.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
NASC, 9-year financial record
Metric 202320222021202020192018201720162015
Revenue $B0.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
Income tax $B0.00.00.00.00.0◌−0.0−0.0−0.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0◌−0.0−0.0−0.0−0.0◌◌◌
EPS, diluted $−0.77−4.18−9.06−37.68−2.20−0.010.000.00−0.02
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %—−358.9−343.0−218.5−116.4———−3477.4
Shares out B0.000.000.000.010.000.440.230.150.15

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 41 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. 10 checks were skipped: cost of revenue is not tagged before 2017. Eight checks were skipped: EPS is not tagged before 2015.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityWholesale-Drugs, Proprietaries & Druggists' Sundries
Listed onOTC market
Incorporated inFlorida
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2015

Share this section

Download image